Daily Brief Health Care: Eli Lilly & Co, Agape ATP, Medpace Holdings Inc, Tempus AI, CareCloud , Telix Pharmaceuticals, Arrowhead Pharmaceuticals , Scribe Therapeutics, Vivos Therapeutics and more

• Eli Lilly has spent the past several years turning Zepbound and Mounjaro into the centerpieces of a rapidly expanding weight-loss and diabetes franchise.
• Now, that momentum is being challenged in federal court.
• Novo Nordisk alleges that Lilly’s advertising misleads consumers by presenting its medicines as outperforming Wegovy and Ozempic, while Lilly maintains that its campaigns accurately reflect direct scientific evidence.

• Agape ATP Corporation is a Nevada corporation engaged in the Health and Wellness Industry, supplying products and advisory services in the Malaysian market. The company is offering units of common.
• Agape ATP Corporation acquired Agape Superior Living Sdn Bhd, securing an established network marketing sales channel in Malaysia for 15 years.
• There is substantial doubt about the Company’s ability to continue as a going concern for the next twelve months.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Medpace is a high-growth, high-margin Contract Research Organization (CRO) that provides full-service clinical trial management, primarily for small to mid-sized biotechnology and pharmaceutical companies.
• The company’s key differentiator is its integrated, ‘high-science’ operational model, which combines therapeutic expertise with end-to-end control over the clinical trial process, including in-house labs and imaging. This approach resonates with clients who require deep scientific support and reliable execution for complex trials.
• While Medpace has a strong track record of organic growth and profitability, recent concerns have emerged regarding a declining book-to-bill ratio, signaling a potential slowdown in new business wins and increased cancellations. This, combined with a premium valuation relative to peers, presents a key risk for investors.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Tempus AI has moved to deepen its position in precision oncology through a definitive agreement to acquire Personalis, its existing partner in molecular residual disease testing.
• Announced on July 20, 2026, the transaction values the remaining Personalis equity at $16.25 per share and implies an enterprise value of roughly $1.5 billion, net of Tempus’ existing stake.
• The consideration is structured primarily as stock, although Tempus may elect to fund up to half in cash, with closing expected in late 2026 or early 2027, subject to shareholder and regulatory approvals.

• Opaque Capital Structure and Going-Concern Risk: Despite a nominal asset base of $24.91 million, Agape ATP is in severe financial distress with only $220,779 in cash against an accumulated deficit of $12.13 million. Virtually all of the company’s current assets ($24.12 million) are tied up in an unallocated, illiquid investment deposit with Bi Cheng Investment Management, raising massive red flags about capital recoverability and solvency.
• MLM Segment in Structural Decline: The core network marketing business (Agape Superior Living) is deteriorating, with management aggressively cutting MLM expenses by 53.5% in a desperate pivot. The network suffers from extreme distributor concentration and high churn, meaning the departure of a few key multi-level marketing leaders in Malaysia could instantly trigger a complete collapse of their remaining sales pipeline.
• Renewable Energy Pivot is Executionally Unfeasible: The company’s highly publicized green energy ventures—including a 300 MWp solar farm in Sabah and 50 EV charging stations—are viewed as paper-only press releases designed to pump speculative retail interest. With near-zero cash and no technical track record, the company cannot meet the strict capital and compliance hurdles set by Malaysian regulators like the Sustainable Energy Development Authority (SEDA).

• The “SaaS” label is marketing; the reality is a low-margin, high-touch services business. While pure software segments boast gross margins above 70%, CareCloud’s consolidated GAAP gross margins hover in the 33% to 35% range. The structural drag comes from high-touch implementation, manual legacy data cleanups, and the intensive operational labor required to run Revenue Cycle Management (RCM), despite aggressive offshoring to Pakistan.
• Customer churn is structurally high and driven by consolidation, not product failure. Churn in their core target market—independent practices with 1 to 10 providers—is structurally high at 12% to 14% annually. As independent practices are acquired by larger health systems or private equity-backed groups, they are systematically migrated off CareCloud to enterprise platforms like Epic or Athenahealth.
• The M&A-driven growth engine has run out of fuel. CareCloud’s historical strategy of buying distressed RCM books of business at 0.3x to 0.5x revenue and cutting costs via offshore migration is no longer viable. High debt service costs on their credit facilities, combined with a lack of organic cross-sell conversion (which remains below 8%), has forced the company into a defensive restructuring posture.

• Telix has continued to outperform operationally in 2026, but future upside is increasingly dependent on pipeline execution, regulatory approvals and therapeutic progress PSMA imaging continues to gain market share Higher R&D spending accelerates pipeline development Regulatory catalysts could drive the next re-rating

• On July 22, 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) announced positive results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG).
• The results shared by the company included a 79% and 81% median triglyceride reduction from baseline in SHASTA-3 and SHASTA-4, respectively.
• In addition, Arrowhead reported a statistically significant reduction in acute pancreatitis (AP) events versus placebo, including a 100% event reduction in high-risk patients (TG > 880 mg/dL and a history of AP).

• Strategic backing includes a $7.5 million private placement from Sanofi affiliates and an anchor investment indication from Eli Lilly.
• Scribe is developing next-generation CRISPR therapies targeting large cardiovascular markets, with initial Phase 1 data expected in 1H 2027.
• Although early-stage and small in size, strong institutional sponsorship and industry validation support an optimistic view on the offering.

• Near-term debt obligation reduced, strengthening the balance sheet.
• On July 15, 2026, Seneca Partners filed a Schedule 13D confirming that its affiliated V-Co Investors converted $1.1 million of convertible debt into equity as part of a $1.6-million financing, reducing near-term debt obligations and simplifying Vivos’ capital structure while reinforcing support from an existing anchor investor.
• The Streeterville secured note remains outstanding, with up to $4.5 million conditionally convertible into equity under the extended exchange agreement.